Abstract
Complication rate of ERCP is about 2%, mortality rate 0,2%. In about 1% acute pancreatitis or recurrency of chronic pancreatitis occurs. In 20 to 73% a rise of serum amylase is noted without clinical symptoms. In a randomized trial the influence of secretin and gabexate-mesilate (synthetic protease inhibitor) on ERCP-correlated complications was analyzed. Gabexate-mesilate caused a significant decrease of ERCP-induced hyperamylasemias, whereas secretin showed no effect.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Alkaline Phosphatase / blood
-
Amylases / blood*
-
Cholangiopancreatography, Endoscopic Retrograde* / adverse effects
-
Chronic Disease
-
Dose-Response Relationship, Drug
-
Drug Therapy, Combination
-
Female
-
Gabexate
-
Guanidines / therapeutic use*
-
Humans
-
Male
-
Middle Aged
-
Pancreatic Neoplasms / diagnostic imaging
-
Pancreatitis / diagnostic imaging
-
Secretin / therapeutic use*
Substances
-
Guanidines
-
Secretin
-
Gabexate
-
Alkaline Phosphatase
-
Amylases